The immunomodulatory properties of in vitro immunoglobulins are dose-dependent

Acta Neurologica Scandinavica

Volumn 108, Issue 4, 2003, Pages 267-273

  Reske, D ^a   Schoppe, S ^a   Broicher, C ^a   Petereit, Hela Felicitas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Immunoglobulin; Immunomodulation; Interferon gamma; Interleukin 10; Multiple sclerosis; Tumour necrosis factor alpha

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MALE; MULTIPLE SCLEROSIS; PERIPHERAL LYMPHOCYTE; STIMULATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-10; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141789670     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.00123.x     Document Type: Article

References (32)

1. NAVIKAS V, LINK H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996;45:322-33.
2. RIECKMANN P, ALBRECHT M, KITZE B et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44:1523-6.
3. RIECKMANN P, ALBRECHT M, KITZE B et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-8.
4. ROHOWSKY-KOCHAN C, MOLINARO D, COOK SD. Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Mult Scler 2000;6:69-77.
5. BECK J, RONDOT P, CATINOT L, FALCO E, KIRCHNER H, WIETZERBIN J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-23.
6. HIRSCH RL, PANITCH HS, JOHNSON KP. Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Immunol 1985;5:386-9.
7. LU CZ, JENSEN MA, ARNASON BG. Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol 1993;46:123-8.
8. LINK J. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. Acta Neurol Scand 1994;(Suppl. 158):1-58.
9. OLSSON T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995;45:11-5.
10. LINK J, HE B, NAVIKAS V et al. Transforming growth factor-beta 1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis. J Neuroimmunol 1995;58:21-35.
11. NAVIKAS V, HE B, LINK J et al. Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. Brain 1996;119:213-23.
12. NAVIKAS V, LINK J, PALASIK W et al. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol 1995;41:171-8.
13. MILLER A, LANIR N, SHAPIRO S et al. Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases. J Neuroimmunol 1996;64:151-61.
14. KHADEMI M, WALLSTROM E, ANDERSSON M, PIEHL F, DI MARCO R, OLSSON T. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis. J Neuroimmunol 2000;103:202-10.
15. PETEREIT HF, BAMBORSCHKE S, ESSE AD, HEISS WD. Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis. Mult Scler 1997;3:180-3.
16. NEUHAUS O, FARINA C, YASSOURIDIS A et al. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000;97:7452-7.
17. FAZEKAS F, DEISENHAMMER F, STRASSER-FUCHS S, NAHLER G, MAMOLI B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997;349:589-93.
18. SORENSEN PS, WANSCHER B, JENSEN CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-81.
19. STANGEL M, SCHUMACHER HC, RUPRECHT K, BOEGNER F, MARX P. Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro. Immunol Invest 1997;26:569-78.
20. ANDERSSON U, BJORK L, SKANSEN-SAPHIR U, ANDERSSON J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994;139:21-42.
21. PASHOV A, BELLON B, KAVERI SV, KAZATCHKINE MD. A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIG). Mult Scler 1997;3:153-6.
22. ACHIRON A, GABBAY U, GILAD R et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998;50:398-402.
23. ACHIRON A, PRAS E, GILAD R et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992;49:1233-6.
24. ROTHFELDER U, NEU I, PELKA R. Therapy of multiple sclerosis with immunoglobulin G. Munch Med Wochenschr 1982;124:74-8.
25. VAN ENGELEN BG, HOMMES OR, PINCKERS A, CRUYSBERG JR, BARKHOF F, RODRIGUEZ M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992;32:834-5.
26. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
27. ALDER LB, MORGAN LA, SPICKETT GP. Contribution of stabilizing agents present in intravenous immunoglobulin preparations to modulation of mononuclear cell proliferation in vitro. Scand J Immunol 1996;44:585-91.
28. SHARIEF MK, INGRAM DA, SWASH M, THOMPSON EJ. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 1999;52:1833-8.
29. MÜLLER F, AUKRUST P, NORDOY I, FROLAND SS. Possible role of interleukin-10 (IL10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion. Blood 1998;92:3721-9.
30. OCHS HD, FISCHER SH, WEDGWOOD RJ et al. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 1984;76:78-82.
31. KAZATCHKINE MD, KAVERI SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
32. HOMMES OR, FILIPPI M, LIN X, PETEREIT H, EUROPEAN CHARCOT FOUNDATION, RAFAELE OS. Results of the European-Canadian clinical trial of IVIG-treatment in secondary progressive uliple sclerosis (ESIMS). J Neurol 2002;249(Suppl. 1):60.